|
|
|
|
|
| Gonçales Jr.,Fernando Lopes; Vigani,Aline; Gonçales,Neiva; Barone,Antonio Alci; Araújo,Evaldo; Focaccia,Roberto; Oliveira,Umbeliana; Coelho,Henrique Sérgio Morais; Paixao,Jacqueline; Perez,Renata; Lobato,Cirley; Weirich,Judith; Rosa,Heitor; Borges,Andrelina; Vila,Ricardo; Corrêa-Giannella,Maria Lúcia; Ferraz,Maria Lúcia Gomes. |
| Combination therapy with pegylated interferon and ribavirin is considered the new standard therapy for naïve patients with chronic hepatitis C. We evaluated the efficacy and safety of treatment with weight-based peginterferon alpha-2b (1.5 mg/kg per week) plus ribavirin (800-1,200 mg/day) for 48 weeks in naïve, relapser and non-responder (to previous treatment with interferon plus ribavirin) patients with chronic hepatitis C. Sixty-seven naïve, 26 relapser and 40 non-responder patients were enrolled. The overall sustained virological response (SVR) for the intention-to-treat population was 54% for naïve, 62% for relapser and 38% for non-responder patients. In the naïve subgroup, SVR was significantly higher in patients with the non-1 genotype (67%)... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Hepatitis C; Interferon alpha-2b; Therapy. |
| Ano: 2006 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702006000500002 |
| |
|
|
|
